HC Wainwright Begins Coverage on Gyre Therapeutics (NASDAQ:GYRE)

Key Points

• HC Wainwright has initiated coverage of Gyre Therapeutics (NASDAQ:GYRE), offering a "buy" rating with a price target of $18.00, indicating a potential upside of 119.51%.
• Gyre Therapeutics reported Q2 earnings of $0.02 per share, missing consensus estimates and generated revenue of $26.77 million, below the expected $30.80 million.
• Institutional investors have been actively adjusting their positions in Gyre Therapeutics, with notable increases from firms like Wells Fargo and Bank of America.

HC Wainwright started coverage on shares of Gyre Therapeutics (NASDAQ:GYRE - Free Report) in a research report report published on Tuesday, MarketBeat reports. The brokerage issued a buy rating and a $18.00 price target on the stock. HC Wainwright also issued estimates for Gyre Therapeutics' Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.06 EPS, FY2025 earnings at $0.17 EPS, FY2026 earnings at $0.04 EPS and FY2027 earnings at ($0.09) EPS.

Gyre Therapeutics Stock Down 6.5%

GYRE stock traded down $0.54 during mid-day trading on Tuesday, hitting $7.74. 76,302 shares of the company were exchanged, compared to its average volume of 89,665. The firm has a market capitalization of $745.44 million, a P/E ratio of 774.77 and a beta of 1.80. The business has a fifty day simple moving average of $7.58 and a 200-day simple moving average of $8.86. Gyre Therapeutics has a 12-month low of $6.11 and a 12-month high of $19.00.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $26.77 million for the quarter, compared to analysts' expectations of $30.80 million. Gyre Therapeutics had a return on equity of 7.67% and a net margin of 4.08%.

Institutional Trading of Gyre Therapeutics

Hedge funds have recently made changes to their positions in the business. SBI Securities Co. Ltd. increased its stake in shares of Gyre Therapeutics by 87.9% during the second quarter. SBI Securities Co. Ltd. now owns 232,299 shares of the company's stock worth $1,707,000 after buying an additional 108,670 shares during the period. Geode Capital Management LLC increased its stake in shares of Gyre Therapeutics by 28.6% during the second quarter. Geode Capital Management LLC now owns 401,709 shares of the company's stock worth $2,953,000 after buying an additional 89,390 shares during the period. American Century Companies Inc. purchased a new stake in shares of Gyre Therapeutics during the first quarter worth approximately $184,000. Northern Trust Corp increased its stake in shares of Gyre Therapeutics by 9.1% during the fourth quarter. Northern Trust Corp now owns 103,382 shares of the company's stock worth $1,251,000 after buying an additional 8,624 shares during the period. Finally, Advantage Alpha Capital Partners LP increased its stake in shares of Gyre Therapeutics by 54.0% during the first quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company's stock worth $105,000 after buying an additional 4,790 shares during the period. Institutional investors and hedge funds own 23.99% of the company's stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.